

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Valenzuela et al.

**Application No.** 10/527,500

**Filed:** March 11, 2005

**Confirmation No.** 9994

**For:** P. ARIASI POLYPEPTIDES, P.  
PERNICIOSUS POLYPEPTIDES AND  
METHODS OF USE

**FILED VIA EFS**

**Examiner:** Nina Archie

**Art Unit:** 1645

**Attorney Reference No.** 4239-66903-02

FILED VIA ELECTRONIC FILING SYSTEM  
UNITED STATES PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT PURSUANT TO**  
**37 C.F.R. § 1.97(c)**

Listed on the accompanying form PTO-1449 and submitted herewith are two English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement (IDS) is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby states that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. As a result, no fee should be required to file this IDS.

Please charge any fees which may be required in connection with filing this IDS to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By /Anne Carlson/  
Anne Carlson, Ph.D.  
Registration No. 47,472

cc: Docketing